# Risdiplam tablet availability for SMA treatment > Developing situation record from CLSTR: https://clstr.news/situations/risdiplam-tablet-availability-for-sma-treatment > Updated: 2026-10-30T04:27:24.000Z. Sources: 7. Developments: 2. The availability of a new tablet formulation of risdiplam for treating Spinal Muscular Atrophy (SMA) has expanded in different regions. In Italy, the tablet formulation was introduced to complement existing syrup solutions, providing patients with more flexibility in managing daily activities. Medical professionals in Italy noted that while these therapies have changed the natural history of the disease, consistent neonatal screening remains a critical need for early intervention. Subsequently, Brazil’s National Health Surveillance Agency (Anvisa) authorized the registration of Evrysdi Go (risdiplam) in coated tablet form. This approval covers adults and children aged 2 years and older weighing at least 20 kilograms with SMA types 1, 2, or 3. The tablet formulation offers logistical advantages over previous versions, as it can be stored at room temperature and does not require professional reconstitution or constant refrigeration. ## Timeline ### 2026-10-30: Anvisa approves Evrysdi Go tablet for spinal muscular atrophy Anvisa has approved Evrysdi Go (risdiplam) in tablet form for treating spinal muscular atrophy in Brazil, offering a more convenient administration method that does not require refrigeration. 7 sources. https://clstr.news/cluster/anvisa-approves-evrysdi-go-tablet-for-spinal-muscular-atrophy ### 2026-10-13: Risdiplam tablet formulation becomes available in Italy for SMA patients A new tablet formulation of risdiplam is available in Italy for Spinal Muscular Atrophy (SMA), offering improved treatment adherence and greater lifestyle flexibility for patients. 12 sources. https://clstr.news/cluster/risdiplam-tablet-formulation-becomes-available-in-italy-for-sma --- Cite as: Risdiplam tablet availability for SMA treatment. CLSTR, https://clstr.news/situations/risdiplam-tablet-availability-for-sma-treatment